Matchpoint – Ponatinib and Intensive Chemotherapy [UK]

Type of study

Treatment of advanced phases

Current status

No longer recruiting

Study title

Matchpoint – Ponatinib and Intensive Chemotherapy

Scientific title

Management of Transformed Chronic myeloid leukaemia: Ponatinib and intensive chemotherapy: a dose finding study (Clinicaltrialsregister.eu 2012-005629-65)

What is the purpose of the study

The aim of this trial is to find a safe and effective dose of a drug called ponatinib when used in combination with chemotherapy in patients with Chronic Myeloid Leukaemia (CML) whose disease has moved in to blast phase.

What will happen during the study

Key inclusion criteria

Male or female patients of 16 years of age or older with Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) in blast phase (BP).
Patients can be considered for inclusion in the study if they are suitable for intensive chemotherapy, have adequate kidney and liver function as well as normal pancreas function.

Key exclusion criteria

Where can I find additional information

Study sponsor

University of Birmingham

Scientific lead / contact

Professor Mhairi Copland
University of Glasgow
Gartnavel General Hospital
Glasgow G12 0ZD

Principal investigator

Prof. Mhairi Copland
University of Glasgow
Gartnavel General Hospital
Glasgow G12 0ZD

Study centers / principal investigators

United Kingdom

University of Birmingham
CRCTU, Institute of Cancer and Genomic Sciences
Edgbaston, B15 2TH

Glasgow

Leeds

Liverpool

London

Nottingham